Format

Send to

Choose Destination
Cell. 2014 Jan 30;156(3):400-7. doi: 10.1016/j.cell.2013.12.028.

Progeria: a paradigm for translational medicine.

Author information

1
Department of Anesthesia, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA; Department of Pediatrics, Hasbro Children's Hospital and Warren Alpert Medical School of Brown University, Providence, RI 02912, USA. Electronic address: leslie_gordon@brown.edu.
2
Division of Biology and Medicine, Brown University, Providence, RI 02912, USA.
3
Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, 33006 Oviedo, Spain.
4
National Cancer Institute, NIH, Bethesda, MD 20892, USA. Electronic address: mistelit@mail.nih.gov.

Abstract

Rare diseases are powerful windows into biological processes and can serve as models for the development of therapeutic strategies. The progress made on the premature aging disorder Progeria is a shining example of the impact that studies of rare diseases can have.

PMID:
24485450
DOI:
10.1016/j.cell.2013.12.028
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center